A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification.
Boisdron-Celle M, Metges JP, Capitain O, Adenis A, Raoul JL, Lecomte T, Lam YH, Faroux R, Masliah C, Poirier AL, Berger V, Morel A, Gamelin E.
Boisdron-Celle M, et al. Among authors: gamelin e.
Semin Oncol. 2017 Feb;44(1):24-33. doi: 10.1053/j.seminoncol.2017.02.007. Epub 2017 Feb 9.
Semin Oncol. 2017.
PMID: 28395759
Clinical Trial.